Table of Content
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Incidence of Retinal Disorders
4.2.2 Upsurge in Geriatric Population
4.2.3 Increase in Research and Development Investments
4.3 Market Restraints
4.3.1 Increasing Use of Off-label Drugs
4.3.2 Lack of Awareness regarding AMD
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Dry Age related macular degeneration
5.1.2 Wet Age-related macular degeneration
5.2 By Stage of Disease
5.2.1 Early-stage AMD
5.2.2 Intermediate AMD
5.2.3 Late-stage AMD
5.3 By Route of Administration
5.3.1 Intravenous route
5.3.2 Intravitreal route
5.4 By Sales Channel
5.4.1 Ambulatory surgical centers
5.4.2 Hospitals
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche AG.
6.1.2 Novartis AG
6.1.3 Bausch Health Companies Inc.
6.1.4 Pfizer Inc.
6.1.5 Panoptica
6.1.6 Aerie Pharmaceutical Inc.
6.1.7 REGENXBIO Inc.
6.1.8 Ellex
6.1.9 Regeneron Pharmaceuticals, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS